Compound 350: A New Hope for Individuals with Drug-resistant Epilepsy
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Jarvis R, Ng S, Nathanson A, Cardarelli R, Abiraman K, Wade F
. Direct activation of KCC2 arrests benzodiazepine refractory status epilepticus and limits the subsequent neuronal injury in mice. Cell Rep Med. 2023; 4(3):100957.
PMC: 10040380.
DOI: 10.1016/j.xcrm.2023.100957.
View
2.
Cardarelli R, Jones K, Pisella L, Wobst H, McWilliams L, Sharpe P
. The small molecule CLP257 does not modify activity of the K-Cl co-transporter KCC2 but does potentiate GABA receptor activity. Nat Med. 2017; 23(12):1394-1396.
PMC: 7371006.
DOI: 10.1038/nm.4442.
View
3.
Prael Iii F, Kim K, Du Y, Spitznagel B, Sulikowski G, Delpire E
. Discovery of Small Molecule KCC2 Potentiators Which Attenuate Seizure-Like Activity in Cultured Neurons. Front Cell Dev Biol. 2022; 10:912812.
PMC: 9263442.
DOI: 10.3389/fcell.2022.912812.
View
4.
Fisher R
. Redefining epilepsy. Curr Opin Neurol. 2015; 28(2):130-5.
DOI: 10.1097/WCO.0000000000000174.
View
5.
Lee K, Abiraman K, Lucaj C, Ollerhead T, Brandon N, Deeb T
. Inhibiting with-no-lysine kinases enhances K+/Cl- cotransporter 2 activity and limits status epilepticus. Brain. 2021; 145(3):950-963.
PMC: 9050525.
DOI: 10.1093/brain/awab343.
View